In Vitro
 Activity and
 In Vivo
 Efficacy of Anidulafungin in Murine Infections by
 Aspergillus flavus

Pastor, Francisco; Mayayo, Emilio; Salas, Valentina; Guarro, Josep

doi:10.1128/aac.01282-10

Cited by 14 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Echinocandins are an important group of fungistatic drugs [3,144]. An in-vivo study of A. flavus infected mice has shown combination therapy of anidulafungin and voriconazole to be more effective than anidulafungin alone or in some cases better than voriconazole alone.…”

Section: Clinical Management Of Aspergillosis Due To a Flavusmentioning

confidence: 99%

“…An in-vivo study of A. flavus infected mice has shown combination therapy of anidulafungin and voriconazole to be more effective than anidulafungin alone or in some cases better than voriconazole alone. It reduced the fungal load in tissues as well as galactomannan level in the serum of infected mice [144]. IDSA recommends a combination of an echinocandin with voriconazole (weak) for a select group of patients with documented IPA and does not recommend (strong) primary therapy with echinocandins alone [137].…”

Section: Clinical Management Of Aspergillosis Due To a Flavusmentioning

confidence: 99%

See 1 more Smart Citation

Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management

Rudramurthy

Paul

Chakrabarti

et al. 2019

JoF

194

143

View full text Add to dashboard Cite

Aspergillus flavus is the second most common etiological agent of invasive aspergillosis (IA) after A. fumigatus. However, most literature describes IA in relation to A. fumigatus or together with other Aspergillus species. Certain differences exist in IA caused by A. flavus and A. fumigatus and studies on A. flavus infections are increasing. Hence, we performed a comprehensive updated review on IA due to A. flavus. A. flavus is the cause of a broad spectrum of human diseases predominantly in Asia, the Middle East, and Africa possibly due to its ability to survive better in hot and arid climatic conditions compared to other Aspergillus spp. Worldwide, ~10% of cases of bronchopulmonary aspergillosis are caused by A. flavus. Outbreaks have usually been associated with construction activities as invasive pulmonary aspergillosis in immunocompromised patients and cutaneous, subcutaneous, and mucosal forms in immunocompetent individuals. Multilocus microsatellite typing is well standardized to differentiate A. flavus isolates into different clades. A. flavus is intrinsically resistant to polyenes. In contrast to A. fumigatus, triazole resistance infrequently occurs in A. flavus and is associated with mutations in the cyp51C gene. Overexpression of efflux pumps in non-wildtype strains lacking mutations in the cyp51 gene can also lead to high voriconazole minimum inhibitory concentrations. Voriconazole remains the drug of choice for treatment, and amphotericin B should be avoided. Primary therapy with echinocandins is not the first choice but the combination with voriconazole or as monotherapy may be used when the azoles and amphotericin B are contraindicated.

show abstract

Section: Clinical Management Of Aspergillosis Due To a Flavusmentioning

confidence: 99%

Section: Clinical Management Of Aspergillosis Due To a Flavusmentioning

confidence: 99%

Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management

Rudramurthy

Paul

Chakrabarti

et al. 2019

JoF

194

143

View full text Add to dashboard Cite

show abstract

Combined Therapy of Voriconazole and Anidulafungin in Murine Infections by Aspergillus flavus

et al. 2011

View full text Add to dashboard Cite

The efficacy of the combination of anidulafungin (AFG) at 1 mg/kg plus voriconazole (VRC) at 25 mg/kg was evaluated in a murine model of disseminated infection by Aspergillus flavus using three isolates previously tested in vitro. All the combinations showed indifferent in vitro interaction with the exception of one, which showed synergy. In general, the combined treatment prolonged the survival and reduced the fungal load in comparison with AFG alone, and only in a few cases, it improved the results of the VRC monotherapy. The combination of the two drugs and VRC alone reduced the galactomannan levels in serum in comparison with the control group.

show abstract

Current Role of Echinocandins in the Management of Invasive Aspergillosis

Mikulska

Viscoli

2011

Curr Infect Dis Rep

View full text Add to dashboard Cite

Echinocandins are parenteral antifungals with a unique site of action targeting the cell wall synthesis. There are three molecules available, anidulafungin, caspofungin, and micafungin, which have fungicidal and fungistatic activity against Candida and Aspergillus, respectively, and an excellent safety profile. There is consistent proof of clinical activity against Aspergillus for caspofungin, while less is known for micafungin and even lees for anidulafungin. Micafungin and caspofungin have been successfully used in targeted treatment of aspergillosis, prophylaxis, and empirical therapy, both as monotherapy and in combination with other antifungals. Caspofungin is approved for empirical therapy of febrile neutropenia and salvage treatment of invasive aspergillosis, whereas micafungin is only licensed for antifungal prophylaxis in stem cell transplantation.

show abstract

In Vitro Activity and In Vivo Efficacy of Anidulafungin in Murine Infections by Aspergillus flavus

Cited by 14 publications

References 18 publications

Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management

Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management

Combined Therapy of Voriconazole and Anidulafungin in Murine Infections by Aspergillus flavus

Current Role of Echinocandins in the Management of Invasive Aspergillosis

Contact Info

Product

Resources

About